Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Review Of GE’s Vizamyl Shows Caution In The Face Of Alzheimer’s Disease Unknowns

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Regulators approved the PET imaging agent for estimating neuritic plaque density in the brain despite the apparent limited clinical utility of the class.


Related Content

Review Of Reviews: Drug Review Profiles 2014
Review Of Reviews: Drug Review Profiles 2014
Piramal Hopes Depth Of Neuraceq Data Will Provide Contrast For Third Alzheimer’s Imaging Agent
FDA Often Looks Outside The Application, Review Documents Show
The Conundrum Of Alzheimer’s Disease R&D
CMS Sticks To Its Guns: Amyvid Alzheimer’s Screening Not Covered In Medicare Population
Efficacy Signal For Lilly’s Solanezumab Stirs The Alzheimer’s Pot
Lilly Gains Amyvid Approval, But Reimbursement Still A Hurdle
Medicare Coverage For Amyvid Complicated By PET Policy; Lilly Seeks Revision
Avid Amyvid Could Be Approved If Training Improves, Advisory Committee Says


Related Companies

Related Deals




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts